Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy in Stage IIB-IIIB NSCLC
NCT05925530Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 11
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Feb 2024; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05925530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925530.